Skip to content
10-K

Annual Report

REGENERON PHARMACEUTICALS, INC. REGN

0001804220-25-000011

← back to feed
Filed
Feb 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt FY 2024 · Dec 31, 2023 $1.98B
Current Liabilities FY 2024 · Dec 31, 2023 $3.42B
Total Liabilities FY 2024 · Dec 31, 2023 $7.11B
Current Assets FY 2024 · Dec 31, 2023 $19.48B
Total Assets FY 2024 · Dec 31, 2023 $33.08B
Shares Diluted FY 2024 · Dec 31, 2022 113.5M sh
Stock Repurchased FY 2024 · Dec 31, 2022 $2.08B
Capex FY 2024 · Dec 31, 2022 $590.1M
Operating Cash Flow FY 2024 · Dec 31, 2022 $5.01B
Cash And Equivalents FY 2024 · Dec 31, 2022 $3.11B
Eps Diluted FY 2024 · Dec 31, 2022 $38.22
Eps Basic FY 2024 · Dec 31, 2022 $40.51
Sga Expense FY 2024 · Dec 31, 2022 $2.12B
Rd Expense FY 2024 · Dec 31, 2022 $3.59B
Net Income FY 2024 · Dec 31, 2022 $4.34B
Operating Income FY 2024 · Dec 31, 2022 $4.74B
Revenue FY 2024 · Dec 31, 2022 $12.17B
Stockholders Equity FY 2024 · Dec 31, 2021 $18.77B